Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia

Journal of Clinical Psychiatry

Volumn 69, Issue 8, 2008, Pages 1281-1286

  Uchida, Hiroyuki ^a,b   Mamo, David C ^a,b   Kapur, Shitij ^a,b,c   Labelle, Alain ^d   Shammi, Chekkera ^a,b   Mannaert, Erik J L ^e   Mann, Steve W ^a   Remington, Gary ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ROYAL OTTAWA HOSPITAL   (Canada)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; PALIPERIDONE; RACLOPRIDE C 11; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MALE; MONOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 49649110740     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0811     Document Type: Article

References (27)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, second edition. Am J Psychiatry 2004;161(suppl 2):1-56
2. Davis JM. Overview: maintenance therapy in psychiatry, 1: schizophrenia. Am J Psychiatry 1975;132(12):1237-1245
3. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(suppl 5):15-18
4. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163(3):396-401
5. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-1132
6. Herriot P, Kheirani K. Survey of depot antipsychotic prescribing in southern Adelaide. Australas Psychiatry 2005;13(3):253-257
7. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999;156(3):412-418
8. Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995;152(2):173-178
9. Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry 2007 Jan;6:3
10. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006 Aug;67(8):1194-1203
11. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70(1):91-100
12. Tauscher J, Jones C, Remington G, et al. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7(3):317-321
13. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-544
14. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157(4):514-520
15. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161(5):818-825
16. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155(7):921-928
17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276
18. Carson RE, Breier A, de Bartolomeis A, et al. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997;17(4):437-447
19. Mintun MA, Raichle ME, Kilbourn MR, et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15(3):217-227
20. Remington G, Kapur S, Zipursky R. The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol 1998;18(1):82-83
21. Remmerie BM, Sips LL, de Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003 Jan;783(2):461-472
22. Remington G, Seeman P, Shammi C, et al. "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 2005;25(6):611-613
23. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301(6756):837-842
24. Gaebel W, Janner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002 Jan;53(1-2):145-159
25. Gaebel W. Intermittent medication: an alternative? Acta Psychiatr Scand Suppl 1994;382:33-38
26. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006 Jul;85(1-3):222-231
27. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007;164(4):630-637